CO2017011093A2 - Derivados de 6,7-dihidropirido [2,1-a]isoquinolin-2-ona como antagonistas del receptor gpr84, y composiciones que los contienen - Google Patents
Derivados de 6,7-dihidropirido [2,1-a]isoquinolin-2-ona como antagonistas del receptor gpr84, y composiciones que los contienenInfo
- Publication number
- CO2017011093A2 CO2017011093A2 CONC2017/0011093A CO2017011093A CO2017011093A2 CO 2017011093 A2 CO2017011093 A2 CO 2017011093A2 CO 2017011093 A CO2017011093 A CO 2017011093A CO 2017011093 A2 CO2017011093 A2 CO 2017011093A2
- Authority
- CO
- Colombia
- Prior art keywords
- diseases
- dihydropyrid
- isoquinolin
- derivatives
- conditions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 230000004968 inflammatory condition Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 108091006027 G proteins Proteins 0.000 abstract 1
- 102100033864 G-protein coupled receptor 84 Human genes 0.000 abstract 1
- 102000030782 GTP binding Human genes 0.000 abstract 1
- 108091000058 GTP-Binding Proteins 0.000 abstract 1
- 101001069589 Homo sapiens G-protein coupled receptor 84 Proteins 0.000 abstract 1
- 230000003915 cell function Effects 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 208000030172 endocrine system disease Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 230000002314 neuroinflammatory effect Effects 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto de acuerdo con la Fórmula I: (VER IMAGEN ADJUNTA) en donde R1, LA, CyA, RA, R2, R3 y R4 son como se describe en la presente. La presente invención se refiere a compuestos novedosos de acuerdo con la Fórmula I que antagonizan GPR84, un receptor conectado a la proteína G que está involucrado en afecciones inflamatorias, y métodos para la producción de estos nuevos compuestos, composiciones farmacéuticas que comprenden estos compuestos, y métodos para la prevención y/o el tratamiento de afecciones inflamatorias, dolor, afecciones neuroinflamatorias, afecciones neurodegenerativas, enfermedades infecciosas, enfermedades autoinmunes, enfermedades endocrinas y/o metabólicas, enfermedades cardiovasculares, leucemia y/o enfermedades que involucran deterioro de las funciones celulares inmunológicas, mediante la administración de un compuesto de la invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506894.3A GB201506894D0 (en) | 2015-04-23 | 2015-04-23 | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| PCT/EP2016/058607 WO2016169911A1 (en) | 2015-04-23 | 2016-04-19 | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017011093A2 true CO2017011093A2 (es) | 2018-01-31 |
Family
ID=53488521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0011093A CO2017011093A2 (es) | 2015-04-23 | 2017-10-30 | Derivados de 6,7-dihidropirido [2,1-a]isoquinolin-2-ona como antagonistas del receptor gpr84, y composiciones que los contienen |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10568879B2 (es) |
| EP (1) | EP3286191B1 (es) |
| JP (1) | JP6777652B2 (es) |
| KR (1) | KR20170139142A (es) |
| CN (1) | CN107531703B (es) |
| AR (1) | AR104362A1 (es) |
| AU (1) | AU2016251517A1 (es) |
| BR (1) | BR112017022008A2 (es) |
| CA (1) | CA2983342A1 (es) |
| CO (1) | CO2017011093A2 (es) |
| GB (1) | GB201506894D0 (es) |
| IL (1) | IL255109A0 (es) |
| MX (1) | MX2017013382A (es) |
| PH (1) | PH12017501911A1 (es) |
| RU (1) | RU2017134551A (es) |
| SG (1) | SG11201708671RA (es) |
| TW (1) | TW201702243A (es) |
| WO (1) | WO2016169911A1 (es) |
| ZA (1) | ZA201706674B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3403649A1 (en) | 2017-05-16 | 2018-11-21 | Bayer Pharma Aktiengesellschaft | Inhibitors and antagonists of gpr84 for the treatment of endometriosis |
| CN106977483A (zh) * | 2017-06-02 | 2017-07-25 | 遵义医学院 | 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法 |
| SG11202000532SA (en) | 2017-08-09 | 2020-02-27 | Denali Therapeutics Inc | Compounds, compositions and methods |
| KR20200088844A (ko) | 2017-11-15 | 2020-07-23 | 갈라파고스 엔.브이. | 섬유증성 질병 치료에서의 용도를 위한 화합물 및 그의 약학 조성물 |
| WO2020007342A1 (zh) * | 2018-07-06 | 2020-01-09 | 中国科学院上海药物研究所 | 联苯磷酸酯类化合物作为gpr84拮抗剂的应用 |
| SG11202108552QA (en) * | 2019-02-13 | 2021-09-29 | Denali Therapeutics Inc | Compounds, compositions and methods |
| EP3924341A4 (en) * | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | COMPOUNDS, COMPOSITIONS AND METHODS |
| BR112022011237A2 (pt) | 2019-12-19 | 2022-08-30 | Bayer Ag | Derivados de furoindazol |
| WO2021123394A1 (en) | 2019-12-20 | 2021-06-24 | University Of Copenhagen | G protein-coupled receptor modulators and a pharmaceutical composition |
| EP4298102A1 (en) | 2021-02-23 | 2024-01-03 | Bayer Aktiengesellschaft | Furoindazole derivatives as gpr84 antagonists |
| WO2022218372A1 (zh) * | 2021-04-14 | 2022-10-20 | 武汉人福创新药物研发中心有限公司 | 一种二氢嘧啶并异喹啉酮类衍生物及用途 |
| US20240239804A1 (en) | 2021-04-29 | 2024-07-18 | Bayer Aktiengesellschaft | Furoindazole derivatives as antagonists or inhibitors of gpr84 |
| EP4355743A1 (en) | 2021-06-18 | 2024-04-24 | University of Copenhagen | Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists |
| CN115611944A (zh) | 2021-07-15 | 2023-01-17 | 中国科学院上海药物研究所 | 不对称gpr84拮抗剂及其用途 |
| WO2024083705A1 (en) | 2022-10-18 | 2024-04-25 | Bayer Aktiengesellschaft | Furoindazole derivatives for the treatment of pain |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0926148A1 (en) * | 1997-12-23 | 1999-06-30 | Applied Research Systems Ars Holding N.V. | Benzo (C)quinolizine derivatives, their preparation and use as 5-alphareductases inhibitors |
| WO2005050225A2 (en) * | 2003-10-31 | 2005-06-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84) |
| AU2006284926A1 (en) | 2005-09-02 | 2007-03-08 | Arena Pharmaceuticals, Inc. | Human G protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to MCP-1 expression |
| WO2012037782A1 (en) | 2010-09-20 | 2012-03-29 | Glaxo Group Limited | Tricyclic compounds, preparation methods, and their uses |
| AR089284A1 (es) * | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
| CN104870445B (zh) | 2012-12-20 | 2017-09-15 | 加拉帕戈斯股份有限公司 | 用于治疗炎性疾病的新二氢嘧啶并异喹啉酮类及其药物组合物(gpr84拮抗剂) |
| GB201411241D0 (en) * | 2014-06-25 | 2014-08-06 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
-
2015
- 2015-04-23 GB GBGB1506894.3A patent/GB201506894D0/en not_active Ceased
-
2016
- 2016-04-19 MX MX2017013382A patent/MX2017013382A/es unknown
- 2016-04-19 CA CA2983342A patent/CA2983342A1/en not_active Abandoned
- 2016-04-19 EP EP16720370.2A patent/EP3286191B1/en active Active
- 2016-04-19 BR BR112017022008-3A patent/BR112017022008A2/pt not_active Application Discontinuation
- 2016-04-19 JP JP2017555303A patent/JP6777652B2/ja active Active
- 2016-04-19 SG SG11201708671RA patent/SG11201708671RA/en unknown
- 2016-04-19 WO PCT/EP2016/058607 patent/WO2016169911A1/en active Application Filing
- 2016-04-19 US US15/568,275 patent/US10568879B2/en active Active
- 2016-04-19 CN CN201680023369.1A patent/CN107531703B/zh active Active
- 2016-04-19 KR KR1020177033832A patent/KR20170139142A/ko unknown
- 2016-04-19 RU RU2017134551A patent/RU2017134551A/ru not_active Application Discontinuation
- 2016-04-19 AU AU2016251517A patent/AU2016251517A1/en not_active Abandoned
- 2016-04-21 TW TW105112490A patent/TW201702243A/zh unknown
- 2016-04-22 AR ARP160101128A patent/AR104362A1/es unknown
-
2017
- 2017-10-04 ZA ZA2017/06674A patent/ZA201706674B/en unknown
- 2017-10-18 IL IL255109A patent/IL255109A0/en unknown
- 2017-10-19 PH PH12017501911A patent/PH12017501911A1/en unknown
- 2017-10-30 CO CONC2017/0011093A patent/CO2017011093A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3286191A1 (en) | 2018-02-28 |
| AU2016251517A1 (en) | 2017-10-26 |
| GB201506894D0 (en) | 2015-06-10 |
| PH12017501911A1 (en) | 2018-03-05 |
| US20190062325A1 (en) | 2019-02-28 |
| IL255109A0 (en) | 2017-12-31 |
| ZA201706674B (en) | 2019-07-31 |
| RU2017134551A (ru) | 2019-04-04 |
| BR112017022008A2 (pt) | 2018-07-03 |
| SG11201708671RA (en) | 2017-11-29 |
| AR104362A1 (es) | 2017-07-12 |
| EP3286191B1 (en) | 2020-07-29 |
| US10568879B2 (en) | 2020-02-25 |
| TW201702243A (zh) | 2017-01-16 |
| WO2016169911A1 (en) | 2016-10-27 |
| JP2018513180A (ja) | 2018-05-24 |
| CA2983342A1 (en) | 2016-10-27 |
| CN107531703A (zh) | 2018-01-02 |
| KR20170139142A (ko) | 2017-12-18 |
| CN107531703B (zh) | 2020-09-01 |
| MX2017013382A (es) | 2017-12-07 |
| JP6777652B2 (ja) | 2020-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017011093A2 (es) | Derivados de 6,7-dihidropirido [2,1-a]isoquinolin-2-ona como antagonistas del receptor gpr84, y composiciones que los contienen | |
| CO2018012171A2 (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
| EA201891099A1 (ru) | 7-(тиазол-5-ил)пирролопиримида в качестве агониста рецептора tlr7 | |
| PH12019500393A1 (en) | Substituted pyrrolizine compounds and uses thereof | |
| CU20210009A7 (es) | Compuestos derivados de tieno pirrolo-triazina acetamida sustituida como inhibidores de la actividad inflamatoria de la proteína receptora tipo nod 3 (nlrp3) | |
| CL2018001624A1 (es) | Antagonistas policíclicos del tlr7/8 y uso de los mismos en el tratamiento de trastornos inmunitarios | |
| MX2021002978A (es) | Lactamas biciclicas y metodos de uso de las mismas. | |
| EA201792515A1 (ru) | ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ ТЕТРАГИДРОХИНОЛИНОНА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕТИНОИДНЫХ ОРФАНОВЫХ РЕЦЕПТОРОВ ГАММА (RORγ) | |
| PH12018500904A1 (en) | Peptide macrocycles against acinetobacter baumannii | |
| UY37007A (es) | Compuestos derivados de purinas, estimuladores de genes de interferón | |
| CU20170162A7 (es) | Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen | |
| CO2020000056A2 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de la fibrosis | |
| EA201592144A1 (ru) | Производное фенола, способ его получения и его применение в медицине | |
| CL2018000289A1 (es) | Compuestos nuevos como moduladores de ror gamma. | |
| CO2020011852A2 (es) | Inhibidores de canales receptores de potencial transitorio de oxadiazol | |
| MY196788A (en) | Fused tricyclic ?-amino acid derivative, preparation method therefor, and medical use thereof | |
| CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
| PE20160687A1 (es) | Analogos de heteroaril indol biciclico utiles como moduladores de ror | |
| CL2018002089A1 (es) | Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso | |
| MX2020004810A (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas. | |
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| CO2021014223A2 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios | |
| EA201791600A1 (ru) | Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора | |
| AR104731A1 (es) | Benzamidas sustituidas y métodos para utilizarlas | |
| EA201700042A1 (ru) | Соединения имидазопиридазина |